(secondQuint)Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment.

 All patients in this trial will receive the investigational (chemotherapy) drug at an optimal dose as determined by previous clinical trials.

 The investigational drug is given through a vein once every three weeks.

 This drug prevents tumor cells from dividing, so they may stop growing or die.

.

 Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment@highlight

The purpose of this clinical trial is to determine if the investigational drug is able to reduce/shrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.

